Six additional programs were implemented between 2018 and the first quarter of 2020 (coronary artery disease, type 2 diabetes, post-coronary artery bypass graft (CABG), post-acute myocardial infarction/percutaneous intervention (AMI/PCI), post-ICU, and post-chimeric androgen receptor T-Cell (CAR-T) therapy). This evidence concerns the gene AR and myocardial infarction.